CLLS Quote, Financials, Valuation and Earnings

Biodexa Pharmaceuticals PLC has a net margin of 46.57% compared to Cellectis SA's net margin of --. Cellectis SA's return on equity of -31.46% beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.

Cellectis SA has a consensus price target of $5.80, signalling upside risk potential of 356.69%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.97 which suggests that it could grow by 804.58%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Cellectis SA, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Cellectis SA.

Cellectis SA has a beta of 3.275, which suggesting that the stock is 227.454% more volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.489, suggesting its more volatile than the S&P 500 by 48.943%.

Cellectis SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectis SA pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.

Cellectis SA quarterly revenues are $12.7M, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Cellectis SA's net income of $5.9M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Cellectis SA's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectis SA is 3.01x versus 1.80x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

DBV Technologies SA has a net margin of 46.57% compared to Cellectis SA's net margin of --. Cellectis SA's return on equity of -31.46% beat DBV Technologies SA's return on equity of --.

Cellectis SA has a consensus price target of $5.80, signalling upside risk potential of 356.69%. On the other hand DBV Technologies SA has an analysts' consensus of $21.81 which suggests that it could grow by 313.13%. Given that Cellectis SA has higher upside potential than DBV Technologies SA, analysts believe Cellectis SA is more attractive than DBV Technologies SA.

Cellectis SA has a beta of 3.275, which suggesting that the stock is 227.454% more volatile than S&P 500. In comparison DBV Technologies SA has a beta of 0.707, suggesting its less volatile than the S&P 500 by 29.271%.

Cellectis SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectis SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Cellectis SA quarterly revenues are $12.7M, which are larger than DBV Technologies SA quarterly revenues of --. Cellectis SA's net income of $5.9M is higher than DBV Technologies SA's net income of -$30.4M. Notably, Cellectis SA's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectis SA is 3.01x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Edap TMS SA has a net margin of 46.57% compared to Cellectis SA's net margin of -48.85%. Cellectis SA's return on equity of -31.46% beat Edap TMS SA's return on equity of -42.5%.

Cellectis SA has a consensus price target of $5.80, signalling upside risk potential of 356.69%. On the other hand Edap TMS SA has an analysts' consensus of $10.67 which suggests that it could grow by 368.87%. Given that Edap TMS SA has higher upside potential than Cellectis SA, analysts believe Edap TMS SA is more attractive than Cellectis SA.

Cellectis SA has a beta of 3.275, which suggesting that the stock is 227.454% more volatile than S&P 500. In comparison Edap TMS SA has a beta of 0.372, suggesting its less volatile than the S&P 500 by 62.782%.

Cellectis SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edap TMS SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectis SA pays -- of its earnings as a dividend. Edap TMS SA pays out -- of its earnings as a dividend.

Cellectis SA quarterly revenues are $12.7M, which are smaller than Edap TMS SA quarterly revenues of $14.4M. Cellectis SA's net income of $5.9M is higher than Edap TMS SA's net income of -$7M. Notably, Cellectis SA's price-to-earnings ratio is -- while Edap TMS SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectis SA is 3.01x versus 1.23x for Edap TMS SA. Usually stocks with elevated PS ratios are considered overvalued.

Genfit SA has a net margin of 46.57% compared to Cellectis SA's net margin of --. Cellectis SA's return on equity of -31.46% beat Genfit SA's return on equity of --.

Cellectis SA has a consensus price target of $5.80, signalling upside risk potential of 356.69%. On the other hand Genfit SA has an analysts' consensus of $10.17 which suggests that it could grow by 191.7%. Given that Cellectis SA has higher upside potential than Genfit SA, analysts believe Cellectis SA is more attractive than Genfit SA.

Cellectis SA has a beta of 3.275, which suggesting that the stock is 227.454% more volatile than S&P 500. In comparison Genfit SA has a beta of 1.135, suggesting its more volatile than the S&P 500 by 13.542%.

Cellectis SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genfit SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectis SA pays -- of its earnings as a dividend. Genfit SA pays out -- of its earnings as a dividend.

Cellectis SA quarterly revenues are $12.7M, which are larger than Genfit SA quarterly revenues of --. Cellectis SA's net income of $5.9M is higher than Genfit SA's net income of --. Notably, Cellectis SA's price-to-earnings ratio is -- while Genfit SA's PE ratio is 32.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectis SA is 3.01x versus 2.61x for Genfit SA. Usually stocks with elevated PS ratios are considered overvalued.